However, infliximab (IFX), a chimeric monoclonal antibody against tumor necrosis factor-alpha (TNF-α), remains the drug of choice in acute severe ulcerative colitis (UC) and the preferable first-line choice in biologic naïve patients with moderate to severe UC or Crohn's disease (CD) [1]. The gene discussed is TNF; the disease is Crohn disease.